Sandbox:Roukoz: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 163: | Line 163: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Viral warts | | style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Viral warts''' | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| Line 197: | Line 197: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Nummular eczema | | style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Nummular eczema''' | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| Line 214: | Line 214: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Psoriasis | | style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Psoriasis''' | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| Line 231: | Line 231: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Basal cell carcinoma | | style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Basal cell carcinoma''' | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| Line 248: | Line 248: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Atypical fibroxanthoma | | style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Atypical fibroxanthoma''' | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| Line 265: | Line 265: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Amelanotic melanoma | | style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Amelanotic melanoma''' | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| Line 282: | Line 282: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Cutaneous metastases of internal malignancy | | style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Cutaneous metastases of internal malignancy''' | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| Line 299: | Line 299: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Pyoderma gangrenosum | | style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Pyoderma gangrenosum''' | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| Line 316: | Line 316: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Venous stasis ulcers | | style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Venous stasis ulcers''' | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| Line 333: | Line 333: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Sebaceous Hyperplasia | | style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Sebaceous Hyperplasia''' | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| Line 350: | Line 350: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Traumatic ulcers | | style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Traumatic ulcers''' | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| Line 367: | Line 367: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Bowen Disease | | style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Bowen Disease''' | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| Line 384: | Line 384: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Sebaceous Hyperplasia | | style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Sebaceous Hyperplasia''' | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| Line 401: | Line 401: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Trichoepithelioma | | style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Trichoepithelioma''' | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Revision as of 21:04, 28 January 2019
| Diseases | Clinical manifestations | Para-clinical findings | Gold standard | Additional findings | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Symptoms | Physical examination | ||||||||||||||
| Lab Findings | Imaging | Histopathology | |||||||||||||
| Symptom 1 | Symptom 2 | Symptom 3 | Physical exam 1 | Physical exam 2 | Physical exam 3 | Lab 1 | Lab 2 | Lab 3 | Imaging 1 | Imaging 2 | Imaging 3 | ||||
| Cutaneous squamous cell carcinoma | |||||||||||||||
| Actinic keratoses | |||||||||||||||
| Merkel cell carcinoma | |||||||||||||||
| Prurigo nodules | |||||||||||||||
| Paget disease | |||||||||||||||
| Amelanotic melanoma | |||||||||||||||
| Superficial basal cell carcinoma | |||||||||||||||
| Inflamed seborrheic keratosis | |||||||||||||||
| Viral warts | |||||||||||||||
| Bowenoid papulosis | |||||||||||||||
| Nummular eczema | |||||||||||||||
| Psoriasis | |||||||||||||||
| Basal cell carcinoma | |||||||||||||||
| Atypical fibroxanthoma | |||||||||||||||
| Amelanotic melanoma | |||||||||||||||
| Cutaneous metastases of internal malignancy | |||||||||||||||
| Pyoderma gangrenosum | |||||||||||||||
| Venous stasis ulcers | |||||||||||||||
| Sebaceous Hyperplasia | |||||||||||||||
| Traumatic ulcers | |||||||||||||||
| Bowen Disease | |||||||||||||||
| Sebaceous Hyperplasia | |||||||||||||||
| Trichoepithelioma | |||||||||||||||